liver cancer
Conditions
Interventions
experimental group:Thermal ablation therapy
Sponsors
Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1) Age 18-75 years old, no gender limitation; 2) Liver malignant tumors confirmed by pathology or consistent with clinical diagnosis, including primary liver cancer and metastatic liver cancer; 3) The lesions to be ablated that can be evaluated by imaging: diameter =4cm, number =3; 4) The patient cannot tolerate surgical resection or refuses surgical resection; 5) Child-Pugh A or B, ECOG-PS score =2, expected survival time greater than 3 months.
Exclusion criteria
Exclusion criteria: 1) Child-Pugh C, severe jaundice, especially obstructive jaundice; 2) Diffuse liver cancer, or combined with portal vein trunk to secondary branch or hepatic vein tumor thrombus; 3) Significant liver atrophy, excessive tumor volume, and ablation area needs to reach one-third of the liver volume; 4) With multiple metastases, the expected survival time is less than 3 months; 5) Esophageal ( gastric fundus ) variceal bleeding occurred within 1 month recently; 6) Severe liver, kidney, heart, lung, brain and other major organ function failure; 7) Active infection, especially inflammation of the biliary system; 8) Uncorrectable coagulopathy and severe hematologic abnormalities, with a severe bleeding tendency; 9) Persistent and large amount of ascites, pleural effusion or cachexia; 10) Pregnancy, disturbance of consciousness or unable to cooperate with the treatment; 11) Participated in other clinical studies in the past and are still in the follow-up period; 12) Researchers believe that there are any other factors that are not suitable for enrollment or affect the participation of subjects in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Ablation margin in preoperative abdominal enhanced MRI and immediate postoperative abdominal enhanced CT fusion images;Local tumor recurrence assessment in postoperative abdominal enhanced MRI; | — |
Secondary
| Measure | Time frame |
|---|---|
| Local control rate 6 months after ablation (LCR);Progression-free survival 6 months after ablation (PFS);Overall survival 6 months after ablation (OS); | — |
Countries
China
Contacts
Public ContactXiaoyi Ding
Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
Outcome results
None listed